Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | ACACA | Q13085 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698736 | 1.00 | HSD11B1 (0.39) | HSD11B1AADATACACBACACAHRH3 | |
| SCHEMBL3643325 | 1.00 | HSD11B1 (0.39) | HSD11B1AADATACACBACACAHRH3 | |
| SCHEMBL549461 | 1.00 | HSD11B1 (0.39) | HSD11B1AADATACACBACACAHRH3 | |
| SCHEMBL549462 | 1.00 | HSD11B1 (0.39) | HSD11B1AADATACACBACACAHRH3 | |
| SCHEMBL2700495 | 1.00 | HSD11B1 (0.39) | HSD11B1AADATACACBACACAHRH3 | |
| SCHEMBL2700492 | 1.00 | HSD11B1 (0.39) | HSD11B1AADATACACBACACAHRH3 | |
| SCHEMBL549227 | 0.88 | HSD11B1 (0.39) | HSD11B1AADATHRH3 | |
| SCHEMBL549228 | 0.88 | HSD11B1 (0.39) | HSD11B1AADATHRH3 | |
| SCHEMBL550333 | 0.86 | HSD11B1 (0.39) | HSD11B1AADATHRH3GRM5 | |
| SCHEMBL550334 | 0.86 | HSD11B1 (0.39) | HSD11B1AADATHRH3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873698-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE HOLDINGS CORPORATION (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2173750-B9 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORP (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160280708-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9371323-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE HOLDINGS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2918586-A1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | Incyte Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150210692-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | INCYTE CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| US-9006260-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORPORATION (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2540723-B1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORP (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130018068-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2540723-A1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | Incyte Corporation (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8278318-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2173750-B1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORP (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2173750-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | Incyte Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20080318991-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157752-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018068-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885AADAT 3270/4885ACACB 219/4885 |
| US-20150210692-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885AADAT 3270/4885ACACB 219/4885 |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885AADAT 1625/4885ACACB 1175/4885 |
| US-20160280708-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885AADAT 3270/4885ACACB 219/4885 |
| US-20080318991-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885AADAT 3270/4885ACACB 219/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885AADAT 1625/4885ACACB 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.